Literature DB >> 33351532

Brief Report: HIV-1 Seroconversion Is Not Associated With Prolonged Rectal Mucosal Inflammation.

Cheríe S Blair1, Jordan E Lake2, Ryan C Passaro3, Susan Chavez-Gomez4, Eddy R Segura1,5, Julie Elliott1, Jennifer A Fulcher1, Steven Shoptaw6, Robinson Cabello4, Jesse L Clark1.   

Abstract

OBJECTIVE: Determine the impact of HIV-1 seroconversion on inflammatory cytokines in the rectal mucosa.
SETTING: Secondary analysis of data from men who have sex with men and transgender women who participated in a HIV prevention trial Lima, Peru.
METHODS: From July to December 2017, 605 men who have sex with men and transgender women were screened for rectal gonorrhea/chlamydia (GC/CT). Fifty GC/CT-positive cases were randomly selected and matched with 52 GC/CT-negative controls by age and number of receptive anal intercourse partners in the last month. All participants were HIV-negative at baseline and those with GC/CT at baseline and/or follow-up received appropriate antibiotic therapy. Participants underwent sponge collection of rectal secretions for the measurement of inflammatory cytokines (IL-1β, IL-6, IL-8, and TNF-α) and were screened for rectal GC/CT and HIV at baseline, 3 months, and 6 months. Wilcoxon rank-sum tests compared inflammatory cytokine levels between participants diagnosed with HIV during follow-up and persons who remained HIV-negative.
RESULTS: Eight participants were diagnosed with HIV at the 3-month (n = 6) or 6-month (n = 2) visit. The median number of receptive anal intercourse partners in the month before HIV diagnosis was the same for those who acquired HIV and those who did not. There were no significant differences in inflammatory cytokine levels in rectal mucosa between participants who did and did not experience HIV seroconversion at any time point.
CONCLUSIONS: Despite a surge in viral replication during acute infection, findings from this study suggest that there is no prolonged effect of HIV-1 seroconversion on inflammatory cytokine levels in the rectal mucosa.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33351532      PMCID: PMC7933122          DOI: 10.1097/QAI.0000000000002601

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  14 in total

Review 1.  HIV and mucosal barrier interactions: consequences for transmission and pathogenesis.

Authors:  Adam Burgener; Ian McGowan; Nichole R Klatt
Journal:  Curr Opin Immunol       Date:  2015-07-04       Impact factor: 7.486

Review 2.  Genital inflammation, immune activation and risk of sexual HIV acquisition.

Authors:  Jo-Ann S Passmore; Heather B Jaspan; Lindi Masson
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

3.  Effect of HIV and chlamydia infection on rectal inflammation and cytokine concentrations in men who have sex with men.

Authors:  Marlies Heiligenberg; René Lutter; Dasja Pajkrt; Karin Adams; Henry De Vries; Titia Heijman; Maarten F Schim van der Loeff; Suzanne Geerlings
Journal:  Clin Vaccine Immunol       Date:  2013-07-31

4.  New Human Immunodeficiency Virus Diagnosis Independently Associated With Rectal Gonorrhea and Chlamydia in Men Who Have Sex With Men.

Authors:  Lindley A Barbee; Christine M Khosropour; Julia C Dombrowksi; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2017-07       Impact factor: 2.830

5.  Chronic HIV Infection Is Associated with Upregulation of Proinflammatory Cytokine and Chemokine and Alpha Defensin Gene Expression in Colorectal Mucosa.

Authors:  Jennifer Mait-Kaufman; Esra Fakioglu; Pedro M M Mesquita; Julie Elliott; Yungtai Lo; Rebecca Pellett Madan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-04-08       Impact factor: 2.205

Review 6.  HIV: cell binding and entry.

Authors:  Craig B Wilen; John C Tilton; Robert W Doms
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

7.  Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056).

Authors:  Ian McGowan; Julie Elliott; Galen Cortina; Karen Tanner; Chomchay Siboliban; Amy Adler; Daniel Cho; W John Boscardin; Lydia Soto-Torres; Peter A Anton
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-01       Impact factor: 3.731

8.  Cytokine expression in the colonic mucosa of human immunodeficiency virus-infected individuals before and during 9 months of antiretroviral therapy.

Authors:  Hubert Schulbin; Hagen Bode; Hartmut Stocker; Wolfgang Schmidt; Thomas Zippel; Christoph Loddenkemper; Elisabeth Engelmann; Hans-Jörg Epple; Keikawus Arastéh; Martin Zeitz; Reiner Ullrich
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

Review 9.  Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy.

Authors:  Myron S Cohen; Olivia D Council; Jane S Chen
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396

Review 10.  The immune response during acute HIV-1 infection: clues for vaccine development.

Authors:  Andrew J McMichael; Persephone Borrow; Georgia D Tomaras; Nilu Goonetilleke; Barton F Haynes
Journal:  Nat Rev Immunol       Date:  2009-12-11       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.